Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Speer
Tod W
TW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy / Q000379:methods; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D011897:Random Allocation; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000819:agonists*; D000077204:Temozolomide; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D003606:Dacarbazine; D000077204:Temozolomide